» Authors » Dmitri B Kirpotin

Dmitri B Kirpotin

Explore the profile of Dmitri B Kirpotin including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 43
Citations 2303
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Chen P, Ozawa T, Drummond D, Kalra A, Fitzgerald J, Kirpotin D, et al.
Neuro Oncol . 2012 Dec; 15(2):189-97. PMID: 23262509
Background: Liposomal drug packaging is well established as an effective means for increasing drug half-life, sustaining drug activity, and increasing drug efficacy, whether administered locally or distally to the site...
12.
Kirpotin D, Noble C, Hayes M, Huang Z, Kornaga T, Zhou Y, et al.
Methods Enzymol . 2012 Jan; 502:139-66. PMID: 22208985
Immunoliposomes provide a complementary, and in many instances advantageous, drug delivery strategy to antibody-drug conjugates. Their high carrying capacity of 20,000-150,000 drug molecules/liposome, allows for the use of a significantly...
13.
Serwer L, Noble C, Michaud K, Drummond D, Kirpotin D, Ozawa T, et al.
Neuro Oncol . 2011 Sep; 13(12):1288-95. PMID: 21954443
Achieving effective treatment outcomes for patients with glioblastoma (GBM) has been impeded by many obstacles, including the pharmacokinetic limitations of antitumor agents, such as topotecan (TPT). Here, we demonstrate that...
14.
Dickinson P, LeCouteur R, Higgins R, Bringas J, Larson R, Yamashita Y, et al.
Neuro Oncol . 2010 May; 12(9):928-40. PMID: 20488958
Canine spontaneous intracranial tumors bear striking similarities to their human tumor counterparts and have the potential to provide a large animal model system for more realistic validation of novel therapies...
15.
Drummond D, Noble C, Guo Z, Hayes M, Connolly-Ingram C, Gabriel B, et al.
J Control Release . 2009 Aug; 141(1):13-21. PMID: 19686789
Topotecan (TPT), a highly active anticancer camptothecin drug, would benefit from nanocarrier-mediated site-specific and intracellular delivery because of a labile lactone ring whose hydrolysis inactivates the drug, poor cellular uptake...
16.
Noble C, Guo Z, Hayes M, Marks J, Park J, Benz C, et al.
Cancer Chemother Pharmacol . 2009 Feb; 64(4):741-51. PMID: 19184019
Purpose: Liposome and immunoliposome formulations of two vinca alkaloids, vincristine and vinblastine, were prepared using intraliposomal triethylammonium sucroseoctasulfate and examined for their ability to stabilize the drug for targeted drug...
17.
Drummond D, Noble C, Guo Z, Hayes M, Park J, Ou C, et al.
J Pharmacol Exp Ther . 2008 Oct; 328(1):321-30. PMID: 18948499
Effective liposomal formulations of vinorelbine (5' nor-anhydro-vinblastine; VRL) have been elusive due to vinorelbine's hydrophobic structure and resulting difficulty in stabilizing the drug inside the nanocarrier. Triethylammonium salts of several...
18.
Weng K, Noble C, Papahadjopoulos-Sternberg B, Chen F, Drummond D, Kirpotin D, et al.
Nano Lett . 2008 Aug; 8(9):2851-7. PMID: 18712930
Targeted drug delivery systems that combine imaging and therapeutic modalities in a single macromolecular construct may offer advantages in the development and application of nanomedicines. To incorporate the unique optical...
19.
Dickinson P, LeCouteur R, Higgins R, Bringas J, Roberts B, Larson R, et al.
J Neurosurg . 2008 May; 108(5):989-98. PMID: 18447717
Object: Many factors relating to the safety and efficacy of convection-enhanced delivery (CED) into intracranial tumors are poorly understood. To investigate these factors further and establish a more clinically relevant...
20.
Drummond D, Noble C, Hayes M, Park J, Kirpotin D
J Pharm Sci . 2008 Mar; 97(11):4696-740. PMID: 18351638
Liposomes represent a widely varied and malleable class of drug carriers generally characterized by the presence of one or more amphiphile bilayers enclosing an interior aqueous space. Thus, the pharmacological...